6K465 is a novel and potent small molecule inhibitor based on a pyrimidine scaffold that selectively targets Aurora A kinase.6K465 demonstrates superior ability to reduce the levels of the c-MYC and N-MYC oncoproteins compared to the established inhibitor alisertib; in a comprehensive analysis of its antiproliferative effects, the sensitivities of various small cell lung cancer (SCLC) and breast cancer cell lines to 6K465 were strongly correlated with the baseline protein expression levels of c-MYC and/or N-MYC.